Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: PCK2

Gene summary for PCK2

Gene summary.

Gene information	Species	Human
	Gene symbol	PCK2
	Gene ID	5106
	Gene name	phosphoenolpyruvate carboxykinase 2, mitochondrial
	Gene Alias	PEPCK
	Cytomap	14q11.2-q12
	Gene Type	protein-coding
	GO ID	GO:0001678
	UniProtAcc	A0A0A0MS74

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
5106	PCK2	P8T-E	Human	Esophagus	ESCC	3.35e-10	1.67e-01	0.0889
5106	PCK2	P9T-E	Human	Esophagus	ESCC	2.41e-14	2.86e-01	0.1131
5106	PCK2	P11T-E	Human	Esophagus	ESCC	8.42e-08	2.27e-01	0.1426
5106	PCK2	P12T-E	Human	Esophagus	ESCC	4.91e-39	9.06e-01	0.1122
5106	PCK2	P15T-E	Human	Esophagus	ESCC	6.14e-22	6.80e-01	0.1149
5106	PCK2	P16T-E	Human	Esophagus	ESCC	3.69e-09	2.05e-01	0.1153
5106	PCK2	P17T-E	Human	Esophagus	ESCC	2.82e-03	4.30e-01	0.1278
5106	PCK2	P20T-E	Human	Esophagus	ESCC	4.10e-10	1.25e-01	0.1124
5106	PCK2	P21T-E	Human	Esophagus	ESCC	2.33e-25	6.24e-01	0.1617
5106	PCK2	P22T-E	Human	Esophagus	ESCC	1.30e-07	1.17e-01	0.1236
5106	PCK2	P23T-E	Human	Esophagus	ESCC	5.87e-18	6.41e-01	0.108
5106	PCK2	P24T-E	Human	Esophagus	ESCC	3.85e-13	4.10e-01	0.1287
5106	PCK2	P26T-E	Human	Esophagus	ESCC	3.06e-19	5.15e-01	0.1276
5106	PCK2	P27T-E	Human	Esophagus	ESCC	1.86e-22	4.79e-01	0.1055
5106	PCK2	P28T-E	Human	Esophagus	ESCC	3.10e-26	5.80e-01	0.1149
5106	PCK2	P30T-E	Human	Esophagus	ESCC	6.72e-10	3.62e-01	0.137
5106	PCK2	P31T-E	Human	Esophagus	ESCC	2.74e-40	7.81e-01	0.1251
5106	PCK2	P32T-E	Human	Esophagus	ESCC	2.79e-11	3.39e-01	0.1666
5106	PCK2	P36T-E	Human	Esophagus	ESCC	1.27e-10	2.67e-01	0.1187
5106	PCK2	P37T-E	Human	Esophagus	ESCC	6.75e-16	3.89e-01	0.1371

Page: 1 2 3 4 5 6

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
GC		CAG: Chronic atrophic gastritis
		CAG with IM: Chronic atrophic gastritis with intestinal metaplasia
		CSG: Chronic superficial gastritis
		GC: Gastric cancer
		SIM: Severe intestinal metaplasia
		WIM: Wild intestinal metaplasia
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:0048732	Colorectum	AD	gland development	149/3918	436/18723	6.07e-11	6.33e-09	149
GO:1904951	Colorectum	AD	positive regulation of establishment of protein localization	112/3918	319/18723	2.55e-09	1.80e-07	112
GO:0051222	Colorectum	AD	positive regulation of protein transport	106/3918	303/18723	8.45e-09	5.08e-07	106
GO:0006090	Colorectum	AD	pyruvate metabolic process	47/3918	106/18723	4.85e-08	2.55e-06	47
GO:0032868	Colorectum	AD	response to insulin	91/3918	264/18723	2.02e-07	8.48e-06	91
GO:0071383	Colorectum	AD	cellular response to steroid hormone stimulus	73/3918	204/18723	6.31e-07	2.24e-05	73
GO:1901653	Colorectum	AD	cellular response to peptide	114/3918	359/18723	8.32e-07	2.88e-05	114
GO:0009743	Colorectum	AD	response to carbohydrate	86/3918	253/18723	8.43e-07	2.90e-05	86
GO:0044282	Colorectum	AD	small molecule catabolic process	118/3918	376/18723	1.05e-06	3.55e-05	118
GO:0032869	Colorectum	AD	cellular response to insulin stimulus	72/3918	203/18723	1.10e-06	3.68e-05	72
GO:0071375	Colorectum	AD	cellular response to peptide hormone stimulus	95/3918	290/18723	1.50e-06	4.66e-05	95
GO:0043434	Colorectum	AD	response to peptide hormone	126/3918	414/18723	2.70e-06	7.86e-05	126
GO:0009062	Colorectum	AD	fatty acid catabolic process	41/3918	100/18723	4.02e-06	1.09e-04	41
GO:0034284	Colorectum	AD	response to monosaccharide	76/3918	225/18723	4.64e-06	1.23e-04	76
GO:0061008	Colorectum	AD	hepaticobiliary system development	55/3918	150/18723	6.34e-06	1.59e-04	55
GO:0001889	Colorectum	AD	liver development	54/3918	147/18723	7.20e-06	1.77e-04	54
GO:0033500	Colorectum	AD	carbohydrate homeostasis	84/3918	259/18723	9.10e-06	2.15e-04	84
GO:0009746	Colorectum	AD	response to hexose	73/3918	219/18723	1.20e-05	2.65e-04	73
GO:0031667	Colorectum	AD	response to nutrient levels	138/3918	474/18723	1.22e-05	2.68e-04	138
GO:0009749	Colorectum	AD	response to glucose	71/3918	212/18723	1.31e-05	2.85e-04	71

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa00620	Colorectum	AD	Pyruvate metabolism	28/2092	47/8465	3.71e-07	5.41e-06	3.45e-06	28
hsa00020	Colorectum	AD	Citrate cycle (TCA cycle)	20/2092	30/8465	1.43e-06	1.77e-05	1.13e-05	20
hsa00010	Colorectum	AD	Glycolysis / Gluconeogenesis	34/2092	67/8465	3.63e-06	4.34e-05	2.77e-05	34
hsa04152	Colorectum	AD	AMPK signaling pathway	47/2092	121/8465	3.74e-04	2.82e-03	1.80e-03	47
hsa04922	Colorectum	AD	Glucagon signaling pathway	41/2092	107/8465	1.18e-03	7.75e-03	4.94e-03	41
hsa04964	Colorectum	AD	Proximal tubule bicarbonate reclamation	11/2092	23/8465	1.35e-02	4.86e-02	3.10e-02	11
hsa006201	Colorectum	AD	Pyruvate metabolism	28/2092	47/8465	3.71e-07	5.41e-06	3.45e-06	28
hsa000201	Colorectum	AD	Citrate cycle (TCA cycle)	20/2092	30/8465	1.43e-06	1.77e-05	1.13e-05	20
hsa000101	Colorectum	AD	Glycolysis / Gluconeogenesis	34/2092	67/8465	3.63e-06	4.34e-05	2.77e-05	34
hsa041521	Colorectum	AD	AMPK signaling pathway	47/2092	121/8465	3.74e-04	2.82e-03	1.80e-03	47
hsa049221	Colorectum	AD	Glucagon signaling pathway	41/2092	107/8465	1.18e-03	7.75e-03	4.94e-03	41
hsa049641	Colorectum	AD	Proximal tubule bicarbonate reclamation	11/2092	23/8465	1.35e-02	4.86e-02	3.10e-02	11
hsa006202	Colorectum	SER	Pyruvate metabolism	22/1580	47/8465	9.62e-06	1.33e-04	9.67e-05	22
hsa000202	Colorectum	SER	Citrate cycle (TCA cycle)	16/1580	30/8465	2.06e-05	2.74e-04	1.99e-04	16
hsa049222	Colorectum	SER	Glucagon signaling pathway	38/1580	107/8465	2.57e-05	3.28e-04	2.38e-04	38
hsa000102	Colorectum	SER	Glycolysis / Gluconeogenesis	24/1580	67/8465	6.62e-04	5.36e-03	3.89e-03	24
hsa049642	Colorectum	SER	Proximal tubule bicarbonate reclamation	10/1580	23/8465	5.33e-03	3.28e-02	2.38e-02	10
hsa006203	Colorectum	SER	Pyruvate metabolism	22/1580	47/8465	9.62e-06	1.33e-04	9.67e-05	22
hsa000203	Colorectum	SER	Citrate cycle (TCA cycle)	16/1580	30/8465	2.06e-05	2.74e-04	1.99e-04	16
hsa049223	Colorectum	SER	Glucagon signaling pathway	38/1580	107/8465	2.57e-05	3.28e-04	2.38e-04	38

Page: 1 2 3 4 5

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

PCK2

SNV

Missense_Mutation

c.1014N>C

p.Glu338Asp

p.E338D

Q16822

protein_coding

tolerated(1)

benign(0.003)

TCGA-BH-A0E2-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

doxorubicin

PCK2

SNV

Missense_Mutation

rs559309673

c.1285C>T

p.Arg429Cys

p.R429C

Q16822

protein_coding

deleterious(0.02)

possibly_damaging(0.785)

TCGA-BH-A18G-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK2

SNV

Missense_Mutation

c.1270N>C

p.Phe424Leu

p.F424L

Q16822

protein_coding

deleterious(0)

probably_damaging(0.996)

TCGA-D8-A1JK-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

PCK2

SNV

Missense_Mutation

novel

c.530N>G

p.Gln177Arg

p.Q177R

Q16822

protein_coding

deleterious(0.02)

probably_damaging(0.993)

TCGA-E9-A1ND-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Hormone Therapy

aromasin

PCK2

SNV

Missense_Mutation

c.1334N>A

p.Pro445His

p.P445H

Q16822

protein_coding

deleterious(0)

possibly_damaging(0.456)

TCGA-E9-A22E-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

cyclophosphane

PCK2

insertion

Nonsense_Mutation

novel

c.1621_1622insTTTACTAACACCATCATTAA

p.Gly541ValfsTer3

p.G541Vfs*3

Q16822

protein_coding

TCGA-A8-A092-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

paclitaxel

PCK2

SNV

Missense_Mutation

rs201059299

c.157N>T

p.Arg53Cys

p.R53C

Q16822

protein_coding

deleterious(0.01)

possibly_damaging(0.606)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

PCK2

SNV

Missense_Mutation

c.996N>C

p.Trp332Cys

p.W332C

Q16822

protein_coding

deleterious(0)

probably_damaging(0.987)

TCGA-JX-A3Q0-01

Cervix

cervical & endocervical cancer

Female

<65

III/IV

Unknown

PCK2

SNV

Missense_Mutation

rs2229660

c.92N>A

p.Arg31Gln

p.R31Q

Q16822

protein_coding

tolerated(0.54)

benign(0.011)

TCGA-MU-A8JM-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

PCK2

SNV

Missense_Mutation

rs765912476

c.311G>A

p.Arg104Gln

p.R104Q

Q16822

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-AA-3663-01

Colorectum

colon adenocarcinoma

Male

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1